Beijing SL Pharmaceutical Co Ltd (002038) — Financial Flexibility Index
Beijing SL Pharmaceutical Co Ltd (002038) has a Financial Flexibility Index of 0.24x as of September 2025. Free cash flow of CN¥77.90 Million (operating CF CN¥66.55 Million minus capex CN¥11.35 Million) represents 0% of total liabilities (CN¥327.96 Million). Also explore Beijing SL Pharmaceutical Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Beijing SL Pharmaceutical Co Ltd Financial Flexibility Index (2003–2025)
Historical Financial Flexibility Index trend for Beijing SL Pharmaceutical Co Ltd across 23 annual periods. Check 002038 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Beijing SL Pharmaceutical Co Ltd (2003–2025)
Year-by-year free cash flow to debt coverage for Beijing SL Pharmaceutical Co Ltd. For the full company profile including market capitalisation, see Beijing SL Pharmaceutical Co Ltd market capitalisation.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.51x | CN¥450.63 Million | CN¥257.66 Million | CN¥883.49 Million | ▼ -64.5% |
| 2024 | 1.44x | CN¥572.87 Million | CN¥225.49 Million | CN¥398.37 Million | ▼ -0.9% |
| 2023 | 1.45x | CN¥678.56 Million | CN¥460.20 Million | CN¥467.72 Million | ▲ +4.0% |
| 2022 | 1.40x | CN¥553.31 Million | CN¥389.82 Million | CN¥396.60 Million | ▼ -13.6% |
| 2021 | 1.62x | CN¥701.54 Million | CN¥464.63 Million | CN¥434.23 Million | ▼ -1.4% |
| 2020 | 1.64x | CN¥671.79 Million | CN¥415.84 Million | CN¥410.09 Million | ▼ -29.5% |
| 2019 | 2.32x | CN¥938.61 Million | CN¥665.83 Million | CN¥403.76 Million | ▲ +53.3% |
| 2018 | 1.52x | CN¥712.55 Million | CN¥485.17 Million | CN¥469.73 Million | ▼ -29.0% |
| 2017 | 2.14x | CN¥610.37 Million | CN¥380.72 Million | CN¥285.67 Million | ▼ -42.4% |
| 2016 | 3.71x | CN¥561.07 Million | CN¥396.86 Million | CN¥151.19 Million | ▼ -13.2% |
| 2015 | 4.28x | CN¥634.55 Million | CN¥504.87 Million | CN¥148.40 Million | ▼ -4.3% |
| 2014 | 4.47x | CN¥616.02 Million | CN¥465.00 Million | CN¥137.92 Million | ▲ +20.3% |
| 2013 | 3.71x | CN¥456.89 Million | CN¥347.41 Million | CN¥123.09 Million | ▼ -39.6% |
| 2012 | 6.15x | CN¥646.49 Million | CN¥398.60 Million | CN¥105.17 Million | ▲ +2.9% |
| 2011 | 5.97x | CN¥301.64 Million | CN¥228.59 Million | CN¥50.52 Million | ▼ -21.0% |
| 2010 | 7.55x | CN¥281.18 Million | CN¥238.13 Million | CN¥37.22 Million | ▲ +35.5% |
| 2009 | 5.57x | CN¥204.86 Million | CN¥174.41 Million | CN¥36.75 Million | ▼ -33.7% |
| 2008 | 8.41x | CN¥217.93 Million | CN¥194.32 Million | CN¥25.91 Million | ▲ +154.0% |
| 2007 | 3.31x | CN¥114.98 Million | CN¥88.36 Million | CN¥34.71 Million | ▼ -4.2% |
| 2006 | 3.46x | CN¥122.50 Million | CN¥57.55 Million | CN¥35.41 Million | ▼ -37.1% |
| 2005 | 5.50x | CN¥128.72 Million | CN¥47.48 Million | CN¥23.42 Million | ▲ +218.3% |
| 2004 | 1.73x | CN¥49.00 Million | CN¥31.26 Million | CN¥28.38 Million | ▲ +35.1% |
| 2003 | 1.28x | CN¥46.99 Million | CN¥30.55 Million | CN¥36.78 Million | — |